These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35081404)

  • 1. Emerging Cholesterol Modulators for Atherosclerotic Cardiovascular Disease.
    Noh S; Mai K; Shaver M; Yong S; Mostaghimi M; Oh G; Radwan MM
    Am J Med Sci; 2022 May; 363(5):373-387. PubMed ID: 35081404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety Issues Associated With the Clinical Application of PCSK9 Inhibitors: Current Findings.
    Wang D; Zhang D
    Cardiol Rev; 2023 May-Jun 01; 31(3):155-161. PubMed ID: 35175957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LDL-Cholesterol-Lowering Therapy.
    Pirillo A; Norata GD; Catapano AL
    Handb Exp Pharmacol; 2022; 270():73-101. PubMed ID: 32350699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
    Goldberg AC; Leiter LA; Stroes ESG; Baum SJ; Hanselman JC; Bloedon LT; Lalwani ND; Patel PM; Zhao X; Duell PB
    JAMA; 2019 Nov; 322(18):1780-1788. PubMed ID: 31714986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent insights into low-density lipoprotein metabolism and therapy.
    Pirillo A; Catapano AL; Norata GD
    Curr Opin Clin Nutr Metab Care; 2021 Mar; 24(2):120-126. PubMed ID: 33394716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.
    Sabatel-Pérez F; García-Ropero A; Santos-Gallego CG; Urooj Zafar M; Badimón JJ
    Drugs Today (Barc); 2019 May; 55(5):329-344. PubMed ID: 31131843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid lowering therapy: implications of recent clinical trials.
    Backes JM; Hilleman DE
    Future Cardiol; 2024 Feb; 20(2):89-98. PubMed ID: 38226457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Cholesterol Paradigm in the Risk Reduction for Atherosclerotic Cardiovascular Disease: Does the Mechanism of Action of Pharmacotherapy Matter for Clinical Outcomes?
    Zhou R; Stouffer GA; Smith SC
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):533-549. PubMed ID: 34138676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.
    Scherer DJ; Nelson AJ; Psaltis PJ; Nicholls SJ
    Intern Med J; 2017 Aug; 47(8):856-865. PubMed ID: 28401639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging drugs for hyperlipidemia.
    Paras C; Hussain MM; Rosenson RS
    Expert Opin Emerg Drugs; 2010 Sep; 15(3):433-51. PubMed ID: 20423271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world use of PCSK9 inhibitors: A single-center experience.
    Sarsam S; Berry A; Degheim G; Singh R; Zughaib M
    J Int Med Res; 2019 Jan; 47(1):265-270. PubMed ID: 30280628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice.
    Rossi M; Fabris E; Barbisan D; Massa L; Sinagra G
    Am J Cardiovasc Drugs; 2022 Mar; 22(2):141-155. PubMed ID: 34514551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
    Alla VM; Agrawal V; DeNazareth A; Mohiuddin S; Ravilla S; Rendell M
    Drugs; 2013 Jul; 73(10):1025-54. PubMed ID: 23754124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP).
    Banach M; Penson PE; Farnier M; Fras Z; Latkovskis G; Laufs U; Paneni F; Parini P; Pirro M; Reiner Ž; Vrablik M; Escobar C
    Prog Cardiovasc Dis; 2023; 79():2-11. PubMed ID: 36889490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.